Table 2.
Demographic of cohort population.
| Anti-dementia drugs | Cohort population | |||
|---|---|---|---|---|
| n (%)* | Female, n (%) | Mean age at drug exposure, year (SD) | Observation time, year (SD) | |
| Donepezil | 4218 (48.75) | 2769 (65.6) | 77.0 (8.0) | 4.4 (2.3) |
| Rivastigmine | 777 (8.98) | 499 (64.2) | 66.0 (7.5) | 4.5 (2.4) |
| Galantamine | 494 (5.71) | 278 (56.3) | 73.6 (9.0) | 6.3 (3.0) |
| Memantine | 1565 (18.09) | 1042 (66.6) | 76.3 (9.0) | 4.4 (2.2) |
| Total AD | 8653† (100) | 5569 (64.4) | 76.4 (8.2) | 4.6 (2.4) |
n indicates the number of subjects. *Percent values indicate the number of anti-dementia medications over total number of firstly diagnosed as Alzheimer’s dementia (AD). †Total number of AD subjects are not equal to the sum of each drug because there are AD patients without any medications such as N-methyl-d-aspartate (NMDA) receptor antagonist (e.g. Memantine) and cholinesterase inhibitors (AChEIs) (e.g. Donepezil, Rivastigmine and Galantamine). The anti-dementia drugs were prescribed within 6 months after diagnosis of AD and initial dual therapy between AChEIs and memantine was possible.